Aldeyra Therapeutics to Participate in Upcoming Conferences

Rhea-AI Summary

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), a biotechnology firm focused on immune-modulating therapies for ocular and systemic diseases, has announced CEO Todd C. Brady's participation in several upcoming investor conferences. These include the Berenberg US CEO Conference on November 10, the Eyecelerator@AAO 2021 on November 11, the Jefferies London Healthcare Conference on November 18, and Ophthalmology Day at BTIG on November 30. Webcasts of these events will be accessible on their Investors & Media page for 90 days.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences:

• Berenberg US CEO Conference
  Format: Analyst-Hosted Fireside Chat
  Date: Wednesday, November 10, 2021
  Time: 10:00 a.m. ET
  Note: A live and recorded webcast of this event will be available on the Investors & Media page of the Company’s website at https://ir.aldeyra.com/. The recorded webcast will be archived and available for 90 days.

• Eyecelerator@AAO 2021
  Format: Retina Showcase Presentation
  Date: Thursday, November 11, 2021
  Time: 1:05 p.m. CT (2:05 p.m. ET)

• Jefferies London Healthcare Conference
  Format: Analyst-Hosted Fireside Chat
  Time: Available On Demand Beginning at 8:00 a.m. GMT (3:00 a.m. ET) Thursday, November 18, 2021
  Note: A webcast of this event will be available on the Investors & Media page of the Company’s website at https://ir.aldeyra.com/. The recorded webcast will be archived and available for 90 days.

• Ophthalmology Day at BTIG
  Format: Analyst-Hosted Fireside Chat
  Date: Tuesday, November 30, 2021
  Time: 1:00 p.m. ET

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the Company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The Company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109006224/en/

Corporate Contact:

Joshua Reed

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

jreed@aldeyra.com

Investor & Media Contact:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 617-542-5300

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.

FAQ

What conferences will Aldeyra Therapeutics participate in November 2021?

Aldeyra Therapeutics will participate in the Berenberg US CEO Conference on November 10, Eyecelerator@AAO 2021 on November 11, Jefferies London Healthcare Conference on November 18, and Ophthalmology Day at BTIG on November 30.

What is the schedule for the Aldeyra Therapeutics conferences?

The schedule includes: Berenberg US CEO Conference at 10:00 a.m. ET on November 10, Eyecelerator@AAO at 2:05 p.m. ET on November 11, Jefferies London Healthcare Conference available on-demand from 3:00 a.m. ET on November 18, and Ophthalmology Day at BTIG at 1:00 p.m. ET on November 30.

Where can I find the webcasts for Aldeyra Therapeutics conferences?

Webcasts for Aldeyra Therapeutics' conferences will be available on their Investors & Media page at https://ir.aldeyra.com/ for 90 days.

Who is the CEO of Aldeyra Therapeutics participating in the conferences?

Todd C. Brady, M.D., Ph.D., is the President and CEO of Aldeyra Therapeutics participating in the conferences.

What are the key drug candidates of Aldeyra Therapeutics?

Aldeyra's key drug candidates include reproxalap and ADX-629, which target RASP mediators of inflammation, currently in Phase 3 clinical trials.